Skip to main content
SpringerLink
Log in

Infectious Diseases: Deep Fungal Infections

  • Chapter
  • First Online:
Therapy in Pediatric Dermatology

  • 1407 Accesses

Abstract

The focus of this chapter is cutaneous infections due to fungi, in particular deep fungal infections, and the available evidence supporting specific treatments, both medical and surgical, for these conditions in children and adolescents. For some infections, adjunctive therapies are recommended in addition to first-line, second-line, and third-line treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. da Rosa AC, Scroferneker ML, Vettorato R, Gervini RL, Vettorato G, Weber A. Epidemiology of sporotrichosis: a study of 304 cases in Brazil. J Am Acad Dermatol. 2005;52(3 Pt 1):451–9.

    Article  PubMed  Google Scholar 

  2. Pérez-Blanco M, Hernández Valles R, García-Humbría L. Yegres Chromoblastomycosis in children and adolescents in the endemic area of the Falcón State. Venezuela Med Mycol. 2006;44(5):467–71.

    Article  PubMed  Google Scholar 

  3. Silva JP, de Souza W, Rozental S. Chromoblastomycosis: a retrospective study of 325 cases on Amazonic Region (Brazil). Mycopathologia. 1998;143(3):171–5.

    Article  PubMed  Google Scholar 

  4. Zijlstra EE, van de Sande WW, Welsh O, el Mahgoub S, Goodfellow M, Fahal AH. Mycetoma: a unique neglected tropical disease. Lancet Infect Dis. 2016;16(1):100–12.

    Article  PubMed  Google Scholar 

  5. Sudarshan V, Goel NK, Gahine R, Krishnani C. Rhinosporidiosis in Raipur, Chhattisgarh: a report of 462 cases. Indian J Pathol Microbiol. 2007;50(4):718–21.

    CAS  PubMed  Google Scholar 

  6. Pal DK, Mallick AA, Majhi TK, Biswas BK, Chowdhury MK. Rhinosporidiosis in southwest Bengal. Trop Doct. 2012;42(3):150–3.

    Article  PubMed  Google Scholar 

  7. Kauffman CA. Sporotrichosis. Clin Infect Dis. 1999;29(2):231–6. quiz 7.

    Article  CAS  PubMed  Google Scholar 

  8. Bernardes-Engemann AR, Costa RC, Miguens BR, Penha CV, Neves E, Pereira BA, et al. Development of an enzyme-linked immunosorbent assay for the serodiagnosis of several clinical forms of sporotrichosis. Med Mycol. 2005;43(6):487–93.

    Article  CAS  PubMed  Google Scholar 

  9. Bonifaz A, Carrasco-Gerard E, Saúl A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses. 2001;44(1–2):1–7.

    Article  CAS  PubMed  Google Scholar 

  10. Ibrahim AI, El Hassan AM, Fahal A, van de Sande WW. A histopathological exploration of the Madurella mycetomatis grain. PLoS One. 2013;8(3):e57774.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Das S, Kashyap B, Barua M, Gupta N, Saha R, Vaid L, et al. Nasal rhinosporidiosis in humans: new interpretations and a review of the literature of this enigmatic disease. Med Mycol. 2011;49(3):311–5.

    Article  PubMed  Google Scholar 

  12. de Lima Barros MB, Schubach AO, de Vasconcellos Carvalhaes de Oliveira R, Martins EB, Teixeira JL, Wanke B. Treatment of cutaneous sporotrichosis with itraconazole--study of 645 patients. Clin Infect Dis. 2011;52(12):e200.

    Article  PubMed  Google Scholar 

  13. Sharkey-Mathis PK, Kauffman CA, Graybill JR, Stevens DA, Hostetler JS, Cloud G, et al. Treatment of sporotrichosis with itraconazole. NIAID Mycoses Study Group. Am J Med. 1993;95(3):279.

    Article  CAS  PubMed  Google Scholar 

  14. Kauffman CA, Bustamante B, Chapman SW, Pappas PG, Infectious Diseases Society of America. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(10):1255.

    Article  CAS  PubMed  Google Scholar 

  15. Cabezas C, Bustamante B, Holgado W, Begue RE. Treatment of cutaneous sporotrichosis with one daily dose of potassium iodide. Pediatr Infect Dis J. 1996;15(4):352.

    Article  CAS  PubMed  Google Scholar 

  16. Gottlieb GS, Lesser CF, Holmes KK, Wald A. Disseminated sporotrichosis associated with treatment with immunosuppressants and tumor necrosis factor-alpha antagonists. Clin Infect Dis. 2003;37(6):838.

    Article  PubMed  Google Scholar 

  17. al-Tawfiq JA, Wools KK. Disseminated sporotrichosis and Sporothrix schenckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin Infect Dis. 1998;26(6):1403.

    Article  CAS  PubMed  Google Scholar 

  18. Hay RJ, Mahgoub ES, Leon G, al-Sogair S, Welsh O. Mycetoma. J Med Vet Mycol. 1992;30(Suppl):1–41.

    PubMed  Google Scholar 

  19. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother. 2009;53(1):24.

    Article  CAS  PubMed  Google Scholar 

  20. McGinnis MR. Mycetoma. Dermatol Clin. 1996;14(1):97.

    Article  CAS  PubMed  Google Scholar 

  21. Welsh O. Mycetoma. Current concepts in treatment. Int J Dermatol. 1991;30(6):387.

    Article  CAS  PubMed  Google Scholar 

  22. Mahgoub ES, Gumaa SA. Ketoconazole in the treatment of eumycetoma due to Madurella mycetomii. Trans R Soc Trop Med Hyg. 1984;78(3):376.

    Article  CAS  PubMed  Google Scholar 

  23. Welsh O, Salinas MC, Rodríguez MA. Treatment of eumycetoma and actinomycetoma. Curr Top Med Mycol. 1995;6:47.

    CAS  PubMed  Google Scholar 

  24. US Food and Drug Administration. FDA Drug Safety Communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. [Online] Available at: http://www.fda.gov/drugs/drugsafety/ucm362415.htm. Accessed 21 Dec 2015.

  25. França Jr GV, Gomes CC, Sakano E, Altemani AM, Shimizu LT. Nasal rhinosporidiosis in children. J Pediatr (Rio J). 1994;70(5):299–301.

    Article  Google Scholar 

  26. George L, Dincy P, Chopra M, Agarwala M, Maheswaran S, Deodhar D, et al. Novel multidrug therapy for disseminated rhinosporidiosis, refractory to dapsone – case report. Trop Doct. 2013;43(3):110–2.

    Article  PubMed  Google Scholar 

  27. Job A, Venkateswaran S, Mathan M, Krishnaswami H, Raman R. Medical therapy of rhinosporidiosis with dapsone. J Laryngol Otol. 1993;107(9):809–12.

    Article  CAS  PubMed  Google Scholar 

  28. Chapman SW, Lin AC, Hendricks KA, Nolan RL, Currier MM, Morris KR, et al. Endemic blastomycosis in Mississippi: epidemiological and clinical studies. Semin Respir Infect. 1997;12(3):219–28.

    CAS  PubMed  Google Scholar 

  29. Garcia Garcia SC, Salas Alanis JC, Flores MG, Gonzalez Gonzalez SE, Vera Cabrera L, Ocampo Candiani J. Coccidioidomycosis and the skin: a comprehensive review. An Bras Dermatol. 2015;90(5):610–9.

    Article  PubMed  Google Scholar 

  30. McCarty JM, Demetral LC, Dabrowski L, Kahal AK, Bowser AM, Hahn JE. Pediatric coccidioidomycosis in central California: a retrospective case series. Clin Infect Dis. 2013;56(11):1579–85.

    Article  PubMed  Google Scholar 

  31. Bicalho RN, Santo MF, de Aguiar MC, Santos VR. Oral paracoccidioidomycosis: a retrospective study of 62 Brazilian patients. Oral Dis. 2001;7(1):56–60.

    Article  CAS  PubMed  Google Scholar 

  32. Ramos ESM, Saraiva Ldo E. Paracoccidioidomycosis. Dermatol Clin. 2008;26(2):257–69. vii.

    Article  CAS  Google Scholar 

  33. Assi MA, Sandid MS, Baddour LM, Roberts GD, Walker RC. Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients. Medicine (Baltimore). 2007;86(3):162–9.

    Article  Google Scholar 

  34. Saccente M, Woods GL. Clinical and laboratory update on blastomycosis. Clin Microbiol Rev. 2010;23(2):367–81.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Wheat LJ. Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host. Transpl Infect Dis. 2006;8(3):128–39.

    Article  CAS  PubMed  Google Scholar 

  36. Monheit JE, Cowan DF, Moore DG. Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. Arch Pathol Lab Med. 1984;108(8):616–8.

    CAS  PubMed  Google Scholar 

  37. Pappagianis D, Zimmer BL. Serology of coccidioidomycosis. Clin Microbiol Rev. 1990;3(3):247–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Zartarian M, Peterson EM, de la Maza LM. Detection of antibodies to Coccidioides immitis by enzyme immunoassay. Am J Clin Pathol. 1997;107(2):148–53.

    Article  CAS  PubMed  Google Scholar 

  39. Durkin M, Connolly P, Kuberski T, Myers R, Kubak BM, Bruckner D, et al. Diagnosis of coccidioidomycosis with use of the Coccidioides antigen enzyme immunoassay. Clin Infect Dis. 2008;47(8):e69–73.

    Article  PubMed  Google Scholar 

  40. Johnson R, Kernerman SM, Sawtelle BG, Rastogi SC, Nielsen HS, Ampel NM. A reformulated spherule-derived coccidioidin (Spherusol) to detect delayed-type hypersensitivity in coccidioidomycosis. Mycopathologia. 2012;174(5–6):353–8.

    Article  PubMed  Google Scholar 

  41. Restrepo A, Tobon AM, Agudelo CA. Paracoccidioidomycosis. In: Hospenthal DR, Rinaldi MG, editors. Diagnosis and treatment of human mycoses. 1st ed. Totowa: Humana Press; 2008. p. 331.

    Chapter  Google Scholar 

  42. Cohen PR, Bank DE, Silvers DN, Grossman ME. Cutaneous lesions of disseminated histoplasmosis in human immunodeficiency virus-infected patients. J Am Acad Dermatol. 1990;23(3 Pt 1):422–8.

    Article  CAS  PubMed  Google Scholar 

  43. Eidbo J, Sanchez RL, Tschen JA, Ellner KM. Cutaneous manifestations of histoplasmosis in the acquired immune deficiency syndrome. Am J Surg Pathol. 1993;17(2):110–6.

    Article  CAS  PubMed  Google Scholar 

  44. Hage CA, Ribes JA, Wengenack NL, Baddour LM, Assi M, McKinsey DS, et al. A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis. 2011;53(5):448–54.

    Article  PubMed  Google Scholar 

  45. Babady NE, Buckwalter SP, Hall L, Le Febre KM, Binnicker MJ, Wengenack NL. Detection of Blastomyces dermatitidis and Histoplasma capsulatum from culture isolates and clinical specimens by use of real-time PCR. J Clin Microbiol. 2011;49(9):3204–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Hage CA, Bowyer S, Tarvin SE, Helper D, Kleiman MB, Wheat LJ. Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy. Clin Infect Dis. 2010;50(1):85–92.

    Article  CAS  PubMed  Google Scholar 

  47. Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(12):1801–12.

    Article  CAS  PubMed  Google Scholar 

  48. Parker JD, Doto IL, Tosh FE. A decade of experience with blastomycosis and its treatment with amphotericin B. A National Communicable Disease Center Cooperative Mycoses Study. Am Rev Respir Dis. 1969;99(6):895–902.

    CAS  PubMed  Google Scholar 

  49. Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis. 2005;40 Suppl 6:S401–8.

    Article  CAS  PubMed  Google Scholar 

  50. Dismukes WE, Bradsher Jr RW, Cloud GC, Kauffman CA, Chapman SW, George RB, et al. Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med. 1992;93(5):489–97.

    Article  CAS  PubMed  Google Scholar 

  51. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Treatment of blastomycosis and histoplasmosis with ketoconazole. Results of a prospective randomized clinical trial. Ann Intern Med. 1985;103(6 (Pt 1):861–72.

    Google Scholar 

  52. Bradsher RW, Rice DC, Abernathy RS. Ketoconazole therapy for endemic blastomycosis. Ann Intern Med. 1985;103(6 (Pt 1):872–9.

    Article  CAS  PubMed  Google Scholar 

  53. Pappas PG, Bradsher RW, Kauffman CA, Cloud GA, Thomas CJ, Campbell Jr GD, et al. Treatment of blastomycosis with higher doses of fluconazole. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1997;25(2):200–5.

    Article  CAS  PubMed  Google Scholar 

  54. Pappas PG, Bradsher RW, Chapman SW, Kauffman CA, Dine A, Cloud GA, et al. Treatment of blastomycosis with fluconazole: a pilot study. The National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis. 1995;20(2):267–71.

    Article  CAS  PubMed  Google Scholar 

  55. Borgia SM, Fuller JD, Sarabia A, El-Helou P. Cerebral blastomycosis: a case series incorporating voriconazole in the treatment regimen. Med Mycol. 2006;44(7):659–64.

    Article  CAS  PubMed  Google Scholar 

  56. Proia LA, Harnisch DO. Successful use of posaconazole for treatment of blastomycosis. Antimicrob Agents Chemother. 2012;56(7):4029.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Williams PL, Mirels LF, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. Ann Intern Med. 2000;133(9):676–86.

    Article  CAS  PubMed  Google Scholar 

  58. Stevens DA, Rendon A, Gaona-Flores V, Catanzaro A, Anstead GM, Pedicone L, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest. 2007;132(3):952–8.

    Article  CAS  PubMed  Google Scholar 

  59. Kim MM, Vikram HR, Kusne S, Seville MT, Blair JE. Treatment of refractory coccidioidomycosis with voriconazole or posaconazole. Clin Infect Dis. 2011;53(11):1060–6.

    Article  CAS  PubMed  Google Scholar 

  60. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, et al. Coccidioidomycosis. Clin Infect Dis. 2005;41(9):1217–23.

    Article  PubMed  Google Scholar 

  61. Shikanai-Yasuda MA, Telles Filho Fde Q, Mendes RP, Colombo AL, Moretti ML. Guidelines in paracoccidioidomycosis. Rev Soc Bras Med Trop. 2006;39(3):297–310.

    Article  PubMed  Google Scholar 

  62. Naranjo MS, Trujillo M, Munera MI, Restrepo P, Gomez I, Restrepo A. Treatment of paracoccidioidomycosis with itraconazole. J Med Vet Mycol. 1990;28(1):67–76.

    Article  CAS  PubMed  Google Scholar 

  63. Shikanai-Yasuda MA, Benard G, Higaki Y, Del Negro GM, Hoo S, Vaccari EH, et al. Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis. Med Mycol. 2002;40(4):411–7.

    Article  CAS  PubMed  Google Scholar 

  64. Queiroz-Telles F, Goldani LZ, Schlamm HT, Goodrich JM, Espinel-Ingroff A, Shikanai-Yasuda MA. An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. Clin Infect Dis. 2007;45(11):1462–9.

    Article  CAS  PubMed  Google Scholar 

  65. Cavalcante Rde S, Sylvestre TF, Levorato AD, de Carvalho LR, Mendes RP. Comparison between itraconazole and cotrimoxazole in the treatment of paracoccidioidomycosis. PLoS Negl Trop Dis. 2014;8(4):e2793.

    Article  PubMed  CAS  Google Scholar 

  66. de Campos EP, Sartori JC, Hetch ML, de Franco MF. Clinical and serologic features of 47 patients with paracoccidioidomycosis treated by amphotericin B. Rev Inst Med Trop Sao Paulo. 1984;26(4):212–7.

    Article  PubMed  Google Scholar 

  67. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105–9.

    Article  CAS  PubMed  Google Scholar 

  68. Wheat J, Hafner R, Korzun AH, Limjoco MT, Spencer P, Larsen RA, et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. Am J Med. 1995;98(4):336–42.

    Article  CAS  PubMed  Google Scholar 

  69. Wheat LJ, Cloud G, Johnson PC, Connolly P, Goldman M, Le Monte A, et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrob Agents Chemother. 2001;45(8):2354–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807–25.

    Article  PubMed  Google Scholar 

  71. Wheat LJ, Connolly P, Haddad N, Le Monte A, Brizendine E, Hafner R. Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrob Agents Chemother. 2002;46(1):248–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Wheat J, MaWhinney S, Hafner R, McKinsey D, Chen D, Korzun A, et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. Am J Med. 1997;103(3):223–32.

    Article  CAS  PubMed  Google Scholar 

  73. Restrepo A, Tobon A, Clark B, Graham DR, Corcoran G, Bradsher RW, et al. Salvage treatment of histoplasmosis with posaconazole. J Infect. 2007;54(4):319–27.

    Article  PubMed  Google Scholar 

  74. Freifeld A, Proia L, Andes D, Baddour LM, Blair J, Spellberg B, et al. Voriconazole use for endemic fungal infections. Antimicrob Agents Chemother. 2009;53(4):1648–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Wheat LJ, Connolly P, Smedema M, Durkin M, Brizendine E, Mann P, et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother. 2006;57(6):1235–9.

    Article  CAS  PubMed  Google Scholar 

  76. van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol. 1998;36(11):3115–21.

    PubMed  PubMed Central  Google Scholar 

  77. Bernardeschi C, Foulet F, Ingen-Housz-Oro S, Ortonne N, Sitbon K, Quereux G, et al. Cutaneous invasive aspergillosis: retrospective multicenter study of the French Invasive-Aspergillosis Registry and literature review. Medicine (Baltimore). 2015;94(26):e1018.

    Article  Google Scholar 

  78. Thomas I, Schwartz RA. Cutaneous manifestations of systemic cryptococcosis in immunosupressed patients. J Med. 2001;32(5–6):259–66.

    CAS  PubMed  Google Scholar 

  79. Du L, Yang Y, Gu J, Chen J, Liao W, Zhu Y. Systemic review of published reports on primary cutaneous cryptococcosis in immunocompetent patients. Mycopathologia. 2015;180(1–2):19–25.

    Article  CAS  PubMed  Google Scholar 

  80. Lenz D, Held J, Goerke S, Wagner D, Tintelnot K, Henneke P, et al. Primary cutaneous cryptococcosis in an eight-year-old immunocompetent child: how to treat? Klin Padiatr. 2015;227(1):41–4.

    Article  CAS  PubMed  Google Scholar 

  81. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev. 2007;20(4):695–704.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Hay RJ. Fusarium infections of the skin. Curr Opin Infect Dis. 2007;20(2):115–7.

    Article  PubMed  Google Scholar 

  83. Adam RD, Hunter G, DiTomasso J, Comerci Jr G. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis. 1994;19(1):67–76.

    Article  CAS  PubMed  Google Scholar 

  84. Arnaiz-Garcia ME, Alonso-Pena D, Gonzalez-Vela Mdel C, Garcia-Palomo JD, Sanz-Gimenez-Rico JR, Arnaiz-Garcia AM. Cutaneous mucormycosis: report of five cases and review of the literature. J Plast Reconstr Aesthet Surg. 2009;62(11):e434–41.

    Article  CAS  PubMed  Google Scholar 

  85. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis. 2006;42(10):1417–27.

    Article  CAS  PubMed  Google Scholar 

  86. Sulahian A, Porcher R, Bergeron A, Touratier S, Raffoux E, Menotti J, et al. Use and limits of (1–3)-beta-d-glucan assay (Fungitell), compared to galactomannan determination (Platelia Aspergillus), for diagnosis of invasive aspergillosis. J Clin Microbiol. 2014;52(7):2328–33.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  87. Cruciani M, Mengoli C, Loeffler J, Donnelly P, Barnes R, Jones BL, et al. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev. 2015;10:CD009551. Lazcano O, Speights Jr VO, Strickler JG, Bilbao JE, Becker J, Diaz J. Combined histochemical stains in the differential diagnosis of Cryptococcus neoformans. Mod Pathol. 1993;6(1):80–4.

    Google Scholar 

  88. Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, Sawatwong P, et al. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin Infect Dis. 2011;53(4):321–5.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Sidrim JJ, Costa AK, Cordeiro RA, Brilhante RS, Moura FE, Castelo-Branco DS, et al. Molecular methods for the diagnosis and characterization of Cryptococcus: a review. Can J Microbiol. 2010;56(6):445–58.

    Article  CAS  PubMed  Google Scholar 

  90. Liu K, Howell DN, Perfect JR, Schell WA. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am J Clin Pathol. 1998;109(1):45–54.

    Article  CAS  PubMed  Google Scholar 

  91. Ostrosky-Zeichner L, Alexander BD, Kett DH, Vazquez J, Pappas PG, Saeki F, et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis. 2005;41(5):654–9.

    Article  CAS  PubMed  Google Scholar 

  92. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634–53.

    Article  PubMed  Google Scholar 

  93. Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol. 2011;49(6):2151–3.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clin Infect Dis. 2008;46(3):327–60.

    Article  CAS  PubMed  Google Scholar 

  95. Upton A, Kirby KA, Carpenter P, Boeckh M, Marr KA. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis. 2007;44(4):531–40.

    Article  PubMed  Google Scholar 

  96. Patterson TF, Boucher HW, Herbrecht R, Denning DW, Lortholary O, Ribaud P, et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis. 2005;41(10):1448–52.

    Article  CAS  PubMed  Google Scholar 

  97. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.

    Article  CAS  PubMed  Google Scholar 

  98. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007;44(1):2–12.

    Article  CAS  PubMed  Google Scholar 

  99. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9.

    Article  CAS  PubMed  Google Scholar 

  100. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, et al. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97(2):135–44.

    Article  CAS  PubMed  Google Scholar 

  101. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563–71.

    Article  CAS  PubMed  Google Scholar 

  102. Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–9.

    Article  PubMed  Google Scholar 

  103. Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006;81(3):320–6.

    Article  CAS  PubMed  Google Scholar 

  104. Caillot D, Thiebaut A, Herbrecht R, de Botton S, Pigneux A, Bernard F, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110(12):2740–6.

    Article  CAS  PubMed  Google Scholar 

  105. Kontoyiannis DP, Boktour M, Hanna H, Torres HA, Hachem R, Raad II. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer. 2005;103(11):2334–7.

    Article  CAS  PubMed  Google Scholar 

  106. Meletiadis J, Petraitis V, Petraitiene R, Lin P, Stergiopoulou T, Kelaher AM, et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J Infect Dis. 2006;194(7):1008–18.

    Article  CAS  PubMed  Google Scholar 

  107. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291–322.

    Article  PubMed  Google Scholar 

  108. Gonzalez CE, Shetty D, Lewis LL, Mueller BU, Pizzo PA, Walsh TJ. Cryptococcosis in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 1996;15(9):796–800.

    Article  CAS  PubMed  Google Scholar 

  109. Manfredi R, Coronado OV, Mastroianni A, Chiodo F. Liposomal amphotericin B and recombinant human granulocyte-macrophage colony-stimulating factor (rHuGM-CSF) in the treatment of paediatric AIDS-related cryptococcosis. Int J STD AIDS. 1997;8(6):406–8.

    Article  CAS  PubMed  Google Scholar 

  110. Brouwer AE, Rajanuwong A, Chierakul W, Griffin GE, Larsen RA, White NJ, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363(9423):1764–7.

    Article  CAS  PubMed  Google Scholar 

  111. van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med. 1997;337(1):15–21.

    Article  PubMed  Google Scholar 

  112. Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368(14):1291–302.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O, French Cryptococcosis Study G. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS One. 2008;3(8):e2870.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  114. Cryptococcus neoformans infections (cryptococcosis). In: Kimberlin DW, Brady MT, Jackson MA, Long SS, editors. Red book: 2015 report of the Committee on Infectious Diseases, 30th ed. Elk Grove Village: American Academy of Pediatrics; 2015. p. 309.

    Google Scholar 

  115. Soltani M, Tobin CM, Bowker KE, Sunderland J, MacGowan AP, Lovering AM. Evidence of excessive concentrations of 5-flucytosine in children aged below 12 years: a 12-year review of serum concentrations from a UK clinical assay reference laboratory. Int J Antimicrob Agents. 2006;28(6):574–7.

    Article  CAS  PubMed  Google Scholar 

  116. Singh N, Lortholary O, Alexander BD, Gupta KL, John GT, Pursell KJ, et al. Antifungal management practices and evolution of infection in organ transplant recipients with cryptococcus neoformans infection. Transplantation. 2005;80(8):1033–9.

    Article  PubMed  Google Scholar 

  117. Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Craven PC, et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks. N Engl J Med. 1987;317(6):334–41.

    Article  CAS  PubMed  Google Scholar 

  118. Pitisuttithum P, Negroni R, Graybill JR, Bustamante B, Pappas P, Chapman S, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother. 2005;56(4):745–55.

    Article  CAS  PubMed  Google Scholar 

  119. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36(9):1122–31.

    Article  CAS  PubMed  Google Scholar 

  120. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98(2):315–9.

    Article  PubMed  Google Scholar 

  121. Nucci M, Marr KA, Vehreschild MJ, de Souza CA, Velasco E, Cappellano P, et al. Improvement in the outcome of invasive fusariosis in the last decade. Clin Microbiol Infect. 2014;20(6):580–5.

    Article  CAS  PubMed  Google Scholar 

  122. Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manag. 2007;3(6):1165–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  123. Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother. 2010;54(10):4446–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis. 2006;42(10):1398–403.

    Article  CAS  PubMed  Google Scholar 

  125. Cornely OA, Ostrosky-Zeichner L, Rahav G, et al. Outcomes in patients with invasive mold disease caused by Fusarium or Scedosporium spp treated with isavuconazole: experience from the VITAL and SECURE trials. (Abstract M-1760) In: Program and abstracts of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC; 2014.

    Google Scholar 

  126. McCarthy M, Rosengart A, Schuetz AN, Kontoyiannis DP, Walsh TJ. Mold infections of the central nervous system. N Engl J Med. 2014;371(2):150–60.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–9.

    Article  PubMed  Google Scholar 

  128. Sun QN, Fothergill AW, McCarthy DI, Rinaldi MG, Graybill JR. In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother. 2002;46(5):1581–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  129. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis. 2006;42(7):e61–5.

    Article  PubMed  Google Scholar 

  130. Pettit NN, Carver PL. Isavuconazole: a new option for the management of invasive fungal infections. Ann Pharmacother. 2015;49(7):825–42.

    Article  CAS  PubMed  Google Scholar 

  131. Reed C, Bryant R, Ibrahim AS, Edwards Jr J, Filler SG, Goldberg R, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis. 2008;47(3):364–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  132. Pfaller MA, Marco F, Messer SA, Jones RN. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diagn Microbiol Infect Dis. 1998;30(4):251–5.

    Article  CAS  PubMed  Google Scholar 

  133. Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother. 2009;53(7):3122–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, et al. The Deferasirox-AmBisome therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67(3):715–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Florida College of Medicine, Gainesville, FL, USA

    Kiran Motaparthi (Assistant Professor)

Authors
  1. Kiran Motaparthi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiran Motaparthi .

Editor information

Editors and Affiliations

  1. Stanford University School of Medicine, Stanford, California, USA

    Joyce M.C. Teng

  2. Stanford University School of Medicine, Stanford, California, USA

    Ann L. Marqueling

  3. Pediatric Dermatology, Joe DiMaggio Children’s Hospital, Hollywood, Florida, USA

    Latanya T. Benjamin

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Motaparthi, K. (2017). Infectious Diseases: Deep Fungal Infections. In: Teng, J., Marqueling, A., Benjamin, L. (eds) Therapy in Pediatric Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-43630-2_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-43630-2_17

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-43628-9

  • Online ISBN: 978-3-319-43630-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation